Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease

Circulation

Volumn 107, Issue 5, 2003, Pages 757-761

  McDermott, Mary McGrae ^a,g   Guralnik, Jack M ^b   Greenland, Philip ^a   Pearce, William H ^a   Criqui, Michael H ^c   Liu, Kiang ^a   Taylor, Lloyd ^d   Chan, Cheeling ^a,d   Sharma, Leena ^a   Schneider, Joseph R ^a,e   Ridker, Paul M ^f   Green, David ^a   Quann, Maureen ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e EVANSTON HOSPITAL   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NONE   (United States)

Author keywords

Inflammation; Peripheral vascular disease; Statins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VASODILATOR AGENT;

ADULT; AGE; AGED; ARTERY DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; EDUCATION; FEMALE; HEALTH INSURANCE; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; SCORING SYSTEM; SEX; STANDING; TASK PERFORMANCE; VELOCITY; WALKING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; ARTERIAL OCCLUSIVE DISEASES; ASPIRIN; BLOOD PRESSURE DETERMINATION; BRACHIAL ARTERY; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; LEG; LOCOMOTION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0037432196     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000050380.64025.07     Document Type: Article

References (27)

1. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methlglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001; 11:1712-1719.
2. Van Haelst PL, van Doormaal JJ, May JF, et al. Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. Eur J Intern Med. 2001;12:503-509.
3. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87-96.
4. Hemandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719.
5. Huhle G, Abletshauser C, Mayer N, et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA reductase inhibitor. Thromb Res. 1999;95:229-234.
6. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level Among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
7. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg functioning and physical activity: the Walking and Leg Circulation study. Ann Intern Med. 2002;136:873-883.
8. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286:1599-1606.
9. McDermott MM, Criqui MH, Liu K, et al. The lower ankle brachial index calculated by averaging the dorsalis pedis and posterior tibial arterial pressures is most closely associated with leg functioning in peripheral arterial disease. J Vasc Surg. 2000;32:1164-1171.
10. Ledue TB, Weiner DL, Sipe JD, et al. Analytical evaluation of particleenhanced immunonephelometric assays for C-reactive protein, serum amyloid A, and mannose binding protein in human serum. Ann Clin Biochem. 1998;35:745-753.
11. Allain CC, Poon LS, Chan CSG, et al. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20:470-475.
12. Sugiuchi H, Ugi Y, Okabe H, et al. Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated a-cyclodextrin. Clin Chem. 1995;41:717-723.
13. Guralnik JM, Fried LP, Simonsick EM, et al. The Women's Health and Aging Study: health and social characteristics of older women with disability. Bethesda, Md: National Institute on Aging; 1995. NIH publication No. 95-4009, appendix E.
14. Altman R, Alarcon G, Appelrouth D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505-514.
15. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Arthritis Rheum. 1986;29:1039-1049.
16. Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of comorbidity with disability in older women: the Women's Health and Aging Study. J Clin Epidemiol. 1999;52:27-37.
17. Montgomery PS, Gardner AW. The clinical utility of a six-minute walk test in peripheral arterial occlusive disease patients. J Am Geriatr Soc. 1998;46:706-711.
18. Guralnik J, Ferrucci L, Simonsick E, et al. Lower extremity function in persons over 70 years as a predictor of subsequent disability. N Engl J Med. 1995;332:556-561.
19. Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol Med Sci. 1994;49:M85-M94.
20. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55:M221-M231.
21. Ferrucci L, Guralnik JM, Salive ME, et al. Effect of age and severity of disability on short-term variation in walking speed: the Women's Health and Aging Study. J Clin Epidemiol. 1996;49:1098-1096.
22. Kurowska EM. Nitric oxide therapies in vascular diseases. Curr Pharm Des. 2002;8:155-166.
23. Stamler JS, Loh E, Roddy MA, et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;91:1314-1319.
24. Visser M, Pahor M, Traffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002; 57:M326-M332.
25. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med. 1991; 151:1769-1776.
26. Rezaie-Majd A, Maca T, Bucek RA, et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patient. Arterioscler Thromb Vasc Biol. 2002;22:1194-1199.
27. Pederson TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998;81:333-335.